Funding for this research was provided by:
Cancer Research UK (C552/A17720, C5255/A20936)
Kay Kendall Leukaemia Fund (KKL1050)
Engineering and Physical Sciences Research Council (EP/L024012/1, NA)
Medical Research Council (NA)
Text and Data Mining valid from 2019-11-21
Received: 12 June 2019
Accepted: 6 November 2019
First Online: 21 November 2019
Ethics approval and consent to participate
: Ascites samples were acquired with informed consent from routine drainage of cancer patients at the Churchill Hospital, Oxford, UK. Ethical approval for the study was gained from the institutional review board and research ethics committee of the Oxford Centre for Histopathology Research (Reference 09/H0606/5 + 5) in accordance with the UK Human Tissue Act 2004 and the Declaration of Helsinki.
: Not applicable.
: LWS, BRC and KDF own equity or share options in PsiOxus Therapeutics (Oxford, UK), which is leading clinical development of EnAd and its derivatives.